Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9209479rdf:typepubmed:Citationlld:pubmed
pubmed-article:9209479lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C0003069lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C1531293lld:lifeskim
pubmed-article:9209479lifeskim:mentionsumls-concept:C0333668lld:lifeskim
pubmed-article:9209479pubmed:issue6lld:pubmed
pubmed-article:9209479pubmed:dateCreated1997-7-22lld:pubmed
pubmed-article:9209479pubmed:abstractTextIt has been suggested that loss of uninfected T cells in HIV infection occurs because of lymphocyte activation resulting in cell death by apoptosis. To address the question of whether cross-linking of CD4/HIV gp120 complexes by antibodies were sufficient to induce T cell depletion in vivo, we developed an animal model of continuous interaction between human CD4 (hCD4), gp120 and anti-gp120 antibodies in the absence of other viral factors. Double-transgenic mice have been generated in which T cells express on their membrane hCD4 and secrete HIV gp120. Although these mice have hCD4/gp120 complexes present on the surface of T cells, they do not show gross immunological abnormalities, and they are able to produce anti-gp120 antibodies following immunization with denaturated gp120. However, double-transgenic mice with antibodies to gp120, when immunized with tetanus toxoid, mount an IgG response that is significantly lower than that of double-transgenic mice without antibodies to gp120. Furthermore, the presence of anti-gp120 antibodies leads to CD4+ T cell depletion and immunodeficiency in the absence of HIV infection. Thus, the antibody response to gp120 can lead to CD4+ T cell attrition in vivo.lld:pubmed
pubmed-article:9209479pubmed:languageenglld:pubmed
pubmed-article:9209479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9209479pubmed:citationSubsetIMlld:pubmed
pubmed-article:9209479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9209479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9209479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9209479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9209479pubmed:statusMEDLINElld:pubmed
pubmed-article:9209479pubmed:monthJunlld:pubmed
pubmed-article:9209479pubmed:issn0014-2980lld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:ForthWWlld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:FantoniAAlld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:FinchHHlld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:AiutiAAlld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:NutiSSlld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:AbrignaniSSlld:pubmed
pubmed-article:9209479pubmed:authorpubmed-author:MangiavacchiL...lld:pubmed
pubmed-article:9209479pubmed:issnTypePrintlld:pubmed
pubmed-article:9209479pubmed:volume27lld:pubmed
pubmed-article:9209479pubmed:ownerNLMlld:pubmed
pubmed-article:9209479pubmed:authorsCompleteYlld:pubmed
pubmed-article:9209479pubmed:pagination1319-24lld:pubmed
pubmed-article:9209479pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:meshHeadingpubmed-meshheading:9209479-...lld:pubmed
pubmed-article:9209479pubmed:year1997lld:pubmed
pubmed-article:9209479pubmed:articleTitleInduction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4.lld:pubmed
pubmed-article:9209479pubmed:affiliationChiron-Vaccines Immunobiology Research Institute, Siena, Italy.lld:pubmed
pubmed-article:9209479pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9209479pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9209479lld:pubmed